6 suspended. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Suspended 6 |
| Phase 1 | 4 | Suspended 4 |
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
| Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma Rituximab, Zanubrutinib, Cyclophosphamide - Diffuse Large B Cell Lymphoma, CD79A Gene Mutation | Phase 2 | Suspended | Henan Cancer Hospital | 59 | 2020-12-25 | 2025-04-25 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
Lymphoma, Large B-Cell, Diffuse (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Epstein-Barr Virus Infections (1) · Immunoblastic Lymphadenopathy (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Recurrence (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma, Non-Hodgkin (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · DNA Virus Infections (2) · Hematologic Diseases (2) · Herpesviridae Infections (2) · Infections (2) · Leukemia (2)
Cyclophosphamide (4) · Prednisone (3) · Rituximab (3) · Vincristine (3) · CT-P10 (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · deltacortene (2) · prednylidene (2) · Asparaginase (1) · Biopsy (1) · E7777 fusion protein (1) · Epirubicin (1) · Etoposide (1) · Filgrastim (1)
Fred Hutchinson Cancer Center (1) · Henan Cancer Hospital (1) · Masonic Cancer Center, University of Minnesota (1) · Northwestern University (1) · SymBio Pharmaceuticals (1) · University of Washington (1)
United States (4) · China (2) · Japan (1) · Singapore (1)
Alexandre V. Hirayama, MD (1) · Reem Karmali, MD (1) · Ryan D. Cassaday, MD (1) · Veronika Bachanova, MD (1) · Yanyan Liu, M.D. Ph.D (1) · Zhihua Yao, M.D. Ph.D (1)
P30CA060553 (1)